牛牛AI助理已提取核心訊息
CRISPR Therapeutics executive Samarth Kulkarni, who serves as both an officer and director, is set to sell 20,000 shares of common stock on January 16, 2024. The shares, valued at an aggregate market value of $1,250,056, were acquired on the same date through the exercise of stock options directly from the issuer. The transaction will be settled in cash. This planned sale follows a period where no securities transactions were reported by Kulkarni in the past three months, as per the latest filings.
CRISPR Therapeutics executive Samarth Kulkarni, who serves as both an officer and director, is set to sell 20,000 shares of common stock on January 16, 2024. The shares, valued at an aggregate market value of $1,250,056, were acquired on the same date through the exercise of stock options directly from the issuer. The transaction will be settled in cash. This planned sale follows a period where no securities transactions were reported by Kulkarni in the past three months, as per the latest filings.
同時擔任高管兼董事的CRISPR Therapeutics高管薩瑪斯·庫爾卡尼定於2024年1月16日出售2萬股普通股。這些股票的總市值爲1,250,056美元，是同日通過直接向發行人行使股票期權收購的。該交易將以現金結算。根據最新文件，此次計劃出售是在庫爾卡尼在過去三個月中沒有報告任何證券交易之後進行的。
同時擔任高管兼董事的CRISPR Therapeutics高管薩瑪斯·庫爾卡尼定於2024年1月16日出售2萬股普通股。這些股票的總市值爲1,250,056美元，是同日通過直接向發行人行使股票期權收購的。該交易將以現金結算。根據最新文件，此次計劃出售是在庫爾卡尼在過去三個月中沒有報告任何證券交易之後進行的。
有用
沒用